Claims
- 1. A pharmaceutical composition for treating a disorder or condition selected from hypertension, depression, generalized anxiety disorder, phobias, posttraumatic stress syndrome, avoidant personality disorder, premature ejaculation, eating disorders, obesity, chemical dependencies, cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders, Parkinson's diseases, endocrine disorders, vasospasm, cerebellar ataxia, gastrointestinal tract disorders, negative symptoms of schizophrenia, premenstrual syndrome, fibromyalgia syndrome, stress incontinence, Tourette's syndrome, trichotillomania, kleptomania, male impotence, attention deficit hyperactivity disorder (ADHD), chronic paroxysmal hemicrania and headache in a mammal, preferably a human, comprising an amount of a compound of formula I or a pharmaceutically acceptable salt thereof that is effective in treating such disorder or condition, and a pharmaceutically acceptable carrier, wherein the compound of formula I is
- 2. A pharmaceutical composition for treating a disorder or condition that can be treated by inhibiting the reuptake of serotonin, dopamine or norepinephrine in a mammal, preferably a human, comprising an amount of a compound of formula I or pharmaceutically acceptable salt thereof that is effective in treating such disorder or condition, and a pharmaceutically acceptable carrier, wherein the compound of formula I is
- 3. A method for treating a disorder or condition selected from hypertension, depression, generalized anxiety disorder, phobias, posttraumatic stress syndrome, avoidant personality disorder, premature ejaculation, eating disorders, obesity, chemical dependencies, cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders, Parkinson's diseases, endocrine disorders, vasospasm, cerebellar ataxia, gastrointestinal tract disorders, negative symptoms of schizophrenia, premenstrual syndrome, fibromyalgia syndrome, stress incontinence, Tourette's syndrome, trichotillomania, kleptomania, male impotence, attention deficit hyperactivity disorder (ADHD), chronic paroxysmal hemicrania and headache in a mammal, comprising administering to a mammal in need of such treatment an amount of a compound of formula I or a pharmaceutically acceptable salt thereof that is effective in treating such disorder or condition, wherein the compound of formula I is
- 4. A method for treating a disorder or condition that can be treated by inhibiting the reuptake of serotonin, dopamine or norepinephrine in a mammal, comprising administering to a mammal in need of such treatment an amount of a compound of formula I or a pharmaceutically acceptable salt thereof that is effective in treating such disorder or condition, wherein the compound of formula I is
- 5. A pharmaceutical composition for treating a condition or disorder that can be treated by inhibiting the reuptake of serotonin, dopamine or norepinephrine in a mammal, comprising:
a) a pharmaceutically acceptable carrier; b) a compound of formula I or a pharmaceutically acceptable salt thereof; and c) an NK-1 receptor antagonist or a 5HT1D receptor antagonist, or a pharmaceutically acceptable salt thereof; wherein the amount of the compound or salt of formula I and the NK-1 receptor antagonist or 5HT1D receptor antagonist are such that the combination is effective in treating such disorder or condition; and wherein the compound of formula I is
A compound of the formula 17wherein phenyl ring A and phenyl ring B can each, independently, be replaced by a naphthyl group, and wherein when phenyl ring A is replaced by a naphthyl group, the ethereal oxygen of structure I and the carbon to which R3, R4 and NR1R2 are attached, are attached to adjacent ring carbon atoms of the naphthyl group and neither of said adjacent ring carbon atoms is also adjacent to a fused ring carbon atom of said naphthyl group; n and m are, selected, independently, from one, two and three; R and R are selected, independently, from hydrogen, (C1-C4)alkyl, (C2-C4)alkenyl, and (C2-C4)alkynyl, or R1and R2, together with the nitrogen to which they are attached, form a four to eight membered saturated ring containing one or two heteroatoms, including the nitrogen to which R1and R2 are attached, wherein the second heteroatom, when present, is selected from oxygen, nitrogen and sulfur, and wherein said ring may optionally be substituted at available binding sites with from one to three substituents selected, independently, from hydroxy and (C1-C6)alkyl; R3 and R4 are selected, independently, from hydrogen and (C1-C4) alkyl optionally substituted with from one to three fluorine atoms, or R3 and R4 together with the carbon to which they are attached, form a four to eight membered saturated carbocyclic ring, and wherein said ring may optionally be substituted at available binding sites with from one to three substituents selected, independently, from hydroxy and (C1-C6)alkyl; or R2 and R3, together with the nitrogen to which R2 is attached and the carbon to which R3 is attached, form a four to eight membered saturated ring containing one or two heteroatoms, including the nitrogen to which R is attached, wherein the second heteroatom, when present, is selected from oxygen, nitrogen and sulfur, and wherein said ring may optionally be substituted at available binding sites with from one to three substituents selected, independently, from hydroxy and (C1-C6)alkyl; each X is selected, independently, from phenyl, heteroaryl and heterocycle, and wherein each X may be further substituted by hydrogen, halo, (C1-C4)alkyl optionally substituted with from one to three fluorine atoms, (C1-C4)alkoxy optionally substituted with from one to three fluorine atoms, cyano, nitro, amino, hydroxy, carbonyl, (C1-C4)alkylamino, di-[(C1-C4)alkyl]amino, NR5(C═O)(C1-C4)alkyl, SO2NR5R6 and SOp(C1-C6)alkyl, wherein R5 and R6 are selected, independently, from hydrogen and (C1-C6)alkyl, and p is zero, one or two; each Y is selected, independently, from hydrogen, halo, (C1-C4)alkyl optionally substituted with from one to three fluorine atoms, (C1-C4)alkoxy optionally substituted with from one to three fluorine atoms, cyano, nitro, amino, (C1-C4)alkylamino, di-[(C1-C4)alkyl]amino, NR5(C═O)(C1-C4)alkyl, SO2NR5R6 and SOp(C1-C6)alkyl, wherein R5 and R6 are selected, independently, from hydrogen and (C1-C6)alkyl, and p is zero, one or two; and each Z is selected independently from hydrogen, halo, (C1-C4)alkyl optionally substituted with from one to three fluorine atoms, (C1-C4)alkoxy.
- 6. A method for treating a disorder or condition that can be treated by inhibiting the reuptake of serotonin, dopamine or norepinephrine in a mammal, comprising administering to a mammal requiring such treatment:
a) a compound of formula I or pharmaceutically acceptable salt thereof; and b) an NK-1 receptor antagonist or 5HT1D receptor antagonist, or a pharmaceutically acceptable salt thereof; wherein the amounts of the compound or salt of formula I and the NK-1 receptor antagonist or 5HT1D receptor antagonist are such that the combination is effective in treating such disorder or condition; and wherein the compound of formula I is 18wherein phenyl ring A and phenyl ring B can each, independently, be replaced by a naphthyl group, and wherein when phenyl ring A is replaced by a naphthyl group, the ethereal oxygen of structure I and the carbon to which R3, R4 and NR1R2 are attached, are attached to adjacent ring carbon atoms of the naphthyl group and neither of said adjacent ring carbon atoms is also adjacent to a fused ring carbon atom of said naphthyl group; n and m are, selected, independently, from one, two and three; R1 and R2 are selected, independently, from hydrogen, (C1-C4)alkyl, (C2-C4)alkenyl, and (C2-C4)alkynyl, or R1and R2, together with the nitrogen to which they are attached, form a four to eight membered saturated ring containing one or two heteroatoms, including the nitrogen to which R1 and R2 are attached, wherein the second heteroatom, when present, is selected from oxygen, nitrogen and sulfur, and wherein said ring may optionally be substituted at available binding sites with from one to three substituents selected, independently, from hydroxy and (C1-C6)alkyl; R3 and R4 are selected, independently, from hydrogen and (C1-C4) alkyl optionally substituted with from one to three fluorine atoms, or R3 and R4 together with the carbon to which they are attached, form a four to eight membered saturated carbocyclic ring, and wherein said ring may optionally be substituted at available binding sites with from one to three substituents selected, independently, from hydroxy and (C1-C6)alkyl; or R2 and R3, together with the nitrogen to which R2 is attached and the carbon to which R3 is attached, form a four to eight membered saturated ring containing one or two heteroatoms, including the nitrogen to which R2 is attached, wherein the second heteroatom, when present, is selected from oxygen, nitrogen and sulfur, and wherein said ring may optionally be substituted at available binding sites with from one to three substituents selected, independently, from hydroxy and (C1-C6)alkyl; each X is selected, independently, from phenyl, heteroaryl and heterocycle, and wherein each X may be further substituted by hydrogen, halo, (C1-C4)alkyl optionally substituted with from one to three fluorine atoms, (C1-C4)alkoxy optionally substituted with from one to three fluorine atoms; cyano, nitro, amino, hydroxy, carbonyl, (C1-C4)alkylamino, di-[(C1-C4)alkyl]amino, NR5(C═O)(C1-C4)alkyl, SO2NR5R6 and SOp(C1-C6)alkyl, wherein R5 and R6 are selected, independently, from hydrogen and (C1-C6)alkyl, and p is zero, one or two; each Y is selected, independently, from hydrogen, halo, (C1-C4)alkyl optionally substituted with from one to three fluorine atoms, (C1-C4)alkoxy optionally substituted with from one to three fluorine atoms, cyano, nitro, amino, (C1-C4)alkylamino, di-[(C1-C4)alkyl]amino, NR5(C═O)(C1-C4)alkyl, SO2NR5R6 and SOp(C1-C6)alkyl, wherein R5 and R6 are selected, independently, from hydrogen and (C1-C6)alkyl, and p is zero, one or two; and each Z is selected independently from hydrogen, halo, (C1-C4)alkyl optionally substituted with from one to three fluorine atoms, (C1-C4)alkoxy.
Parent Case Info
[0001] This application claims priority under 35 U.S.C. 120 of U.S. application Ser. No. 09/692,335, filed Oct. 19, 2000. U.S. application Ser. No. 09/692,335 claims priority of PCT/IB00/01373, filed Sep. 25, 2000, which claims priority of U.S. Application No. 60/167,761, filed Nov. 29, 1999.
Provisional Applications (3)
|
Number |
Date |
Country |
|
60167761 |
Nov 1999 |
US |
|
60167761 |
Nov 1999 |
US |
|
60159276 |
Oct 1999 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
09692335 |
Oct 2000 |
US |
Child |
10153308 |
May 2002 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
PCT/IB00/01373 |
Sep 2000 |
US |
Child |
09692335 |
Oct 2000 |
US |